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The Veterans Administration Cooperative Study on Val-
vular Heart Disease was organized to compare sur vival
and incidence of valve-related complications between pa-
tients receiving a bioprosthesis (the Hancock porcine
heterograft) and a mechanical prosthesis (the Bjork-Shi·
ley spherical disc valve). Five hundred seventy-five pa-
tients undergoing single aortic or mitral valve replace-
ment were randomized at surgery to one of the two valve
types. At an average follow-up of 5 years (range 3 to 8)
there are no statistically significant differences in sur-
vival between patients with the two valve types in the
aortic valve replacement group. There is a statistically
nonsignificant trend toward improved survival in pa-
tients undergoing mitral valve replacement with a bio-
prosthesis compared with a mechanical prosthesis (5 year
sur vival probability was 0.70 ± 0.05 and 0.58 ± 0.06,
respectively).
With in a short time after the first success ful heart valve
replacements with mechanical prostheses by Starr (1) and
Harken (2) and their co workers in 1960, bioprosthetic valves
were introduced (3,4). Thromboembolic complications and
prosthetic valve degeneration , respectively. were major
complications of the earl y mechanical and bioprosthetic
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Fatal and nonfatal valve. related complications oc-
curred significantly less frequently in patients with a
bioprosthesis compared with a mechanical prosthesis for
both mitral and aortic valve replacement. Five year com-
plication-free probability was 0.67 ± 0.05 and 0.45 ±
0.06, respectively, for patients with mitral valve replace-
ment and 0.63 ± 0.04 and 0.53 ± 0.04, respectively,
for those with aortic valve replacement. The difference
in overall complication rates was largely due to the in-
creased number of clinically significant but nonfatal
bleeding episodes in patients receiving a mechanical
prosthesis. Adj ustment for differences in baseline char-
acteristics between patients receiving a mitral mechan-
ical prosthesis and a mitral bioprosthesis reduced the
statistical significance of the difference in both mortality
and complications.
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valves . By the early 1970s it was clear that with refinements
in design , mechanical valves were associated with a lower
incidence of thro mboembolism than previously and were
durable , but patients needed anti coa gulant therapy with the
attendant risks of bleeding . On the other hand, the newer
bioprosthe ses had improved durability , but risk of degen-
eration was still considered significant; the risk of throm-
boembolism appeared low , even though most patients did
not receive an anticoagu lant. Neverthele ss , it is unclear
whether these and oth er differences between a bioprosthe tic
and a mechanical valve will result in significant differences
in patient outcome, because of the differences in patient
characteristics between treatment groups that are known to
occ ur in nonrandomized co mparisons and because the in-
cidence of valve- re lated complications is clearly related to
patient charac teristics (5). It was suggested that comparable
0735-1097/87/$3.50
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Table 1. Exclusions from Randomization
287
110
51
18
100
8
791
216
134
47
35
575
patientgroups would most likely be obtainedonly by a well
designed prospective randomized trial (6).
One of the primary goals of the Veterans Administration
Cooperative Study on Valvular Heart Disease is to compare
survival and valve-related complications between patients
randomized to receive a bioprosthesis or a mechanical pros-
thesis. This is the first report of outcomefrom this random-
ized trial and represents an intermediate duration of follow-
up ranging from 3 to 8 years (average 5).
Methods
The Veterans Administration (VA)Cooperative Studyon
Valvular Heart Disease was organized to address two prin-
cipal goals: I) to compare the incidence of the following
valve-related complications for patients receiving a me-
chanical valve versus patients receiving a bioprosthetic valve:
systemic embolism, valvular regurgitation, prosthesis mal-
function , endocarditis, bleeding and death; and 2) to assess
the capability of quantitative angiographic measures of left
ventricular performance and other clinical and hemody-
namic variables to predictsurvival in patientswithmedically
and surgically treated valvular heart disease. The protocol
has been described in detail (7), but that portion relevant to
the first principal goal, which is the topic of this report,
will be briefly reviewed here.
Patient population. All male patients without life-
threatening disease of other organ systems who were
undergoing cardiac catheterization for native valve disease
at each of 13 participating VA Medical Centers (see Ap-
pendix for listing of participants) and who gave their in-
formed consent wereentered into a registryto identifyprog-
nostic variables (goal 2); between October 1, 1977 and
September 30, 1982, 1,483 patients were entered. Patients
who wererecommended to have singleaorticor mitralvalve
replacement according to usualclinical indications, whodid
not have active endocarditis, who did not have a contrain-
dication to warfarin anticoagulation and who did not have
a requirement for antiplatelet therapy wereasked to consent
to random assignment at surgery to receive a bioprosthetic
valveor a mechanical valve. Randomization wasconducted
by openingan envelopein the operatingroomafterthe valve
ring had been sized because patients requiring a :'519 mm
aortic valve and a :'525 mm mitral valvewereexcluded from
randomization. Randomization was conducted in strata de-
fined by valve position, New York Heart Association func-
tional class I to III versus IV and medical center. For the
first year of the study, patients requiring a 21 or 23 mm
aortic prosthesis were also excluded; with the availability
of the modified orificeHancock valvein 1978,thesepatients
were randomized as a separate subset.
A total of 575 patients were randomized; 110 to the 21
or 23 mm modified orificeHancockand Bjork-Shiley spher-
icaldisc aortic valves, 284 to the ~25 mmstandard Hancock
or Bjork-Shiley spherical disc aortic valves and 181 to the
Hancock or Bjork-Shiley mitral valves . Table I lists the
reasons why 503 of the 1,078 patients undergoing valve
surgery were excluded from randomization. The majority
(287 [57%]) were excluded for failure to meet the protocol
requirements for randomization . Of 791 patients eligible for
randomization, 575 (73%) were randomized . Of 216 pa-
tients eligible for randomization but not randomized, 134
(62%) refused randomization; the operating surgeon made
the decision for a specific valve type in an additional 47
(22%).
Valve surgery. The indications for valve replacement
were those in clinical use by the cardiology-cardiac surgery
teams at each center and were not specified by the trial
protocol. The valve replacement was performed at one of
the participating VA medical centers by a staff cardiac sur-
geon or by a thoracic surgery resident under direct super-
vision of the staff surgeon. The recommendations of the
manufacturers for orientation of the disc or valve leaflets
werefollowed. Concomitant coronaryarterybypassgrafting
was performed in 152 (39%) of 394 patients undergoing
aortic valve replacement and 65 (36%) of 181 patients
undergoing mitral valve replacement; there was no differ-
ence in the frequency of coronary artery bypass surgery
between patients receiving the mechanical versus the bio-
prosthetic valve. In the aortic valve replacement group, two
patients also underwent left ventricular aneurysmectomy;
and in six patients replacement of the ascending aorta was
also performed.
Anticoagulation. Postoperatively, patients with a bio-
prosthesis received warfarin as an anticoagulant for 4 to 8
weeks; anticoagulant therapy could be continued if there
were clinical indications such as deep venous thrombo-
phlebitis, pulmonary embolism or markedly enlarged left
atrium with or without atrial fibrillation . Patients with the
mechanical prosthesis received anticoagulant therapy in-
Total number of patients undergoing 1,078
valve replacement
A. Did not meet protocol
requirements
I. Multiple valve replacement,
tricuspid valve replacement,
or valve repair
2. Small aortic root
3. Active endocarditis
4. Anticoagulation contraindicated
5. Antiplatelet therapy required
B. Met protocol requirements
I. Not randomized
a. Patient refusal
b. Surgeon's decision
c. Other
2. Randomized
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definitely , unless a clear contraindication from life-threat-
ening hemorrhage developed . The recommended level of
anticoagulant was a prothrombin time 2 to 2'12 times the
control value.
Informed consent. The protocoland consentformswere
reviewed and approved by a Human Rights Committee es-
tablished by the VA Cooperative Studies Program Coor-
dinating Center at the VA Medical Center, Hines. Illinois
on May 15 . 1976, as well as the human subject committees
of each of the participating medical centers. Separate in-
formed consent before entry into the registry, before ran-
domization and before postoperativecardiac catheterization
was required.
Data collection. Baseline data collection on standard-
ized forms included relevant information from the history,
physical examination, rest electrocardiogram (ECGl. chest
X-ray film, routine laboratory tests, exercise test when not
contraindicated (by, for example, severe aortic stenosis).
left and right heart catheterization, left ventricular angio-
gram and coronary arteriogram. Certain data items were
believed to be particularly relevant to the goals of this study
and also subject to significant interobserver variability; these
were analyzed in a central laboratory from primary records
(pressure recording or cineangiograms) submitted by par-
ticipating centers. These items were the Estes score (8) and
Sokolow criteria (9) for left ventricular hypertrophy , heart
volume calculated from the chest X-ray film (10) , ST seg-
ment changes on the exercise ECG, chamber dimensions
from the M-mode echocardiogram, valve pressure gradient
and orifice area (II ) and left ventricular volumes (12) from
the contrast angiogram.
Historical . physical examination and laboratory info r-
mation relevant to functional status and valve-related com-
plications was collected at clinic visits every 6 months. In
a few cases the patient was unable or unwilling to travel to
the participating center for follow-up, and the data form
was completed by telephone contact with the patient or his
physician, or both. Follow-up data forms were received for
92% of scheduled visits. However, only 13 patients (2.3%)
withdrew or were lost to follow-up. There was 100% follow-
up in regard to vital status through the use of the VA Ben-
eficiary InformationRetrieval and Locator System (BIRLS).
The accuracy of this system was tested on several occasions
by submission of names of patients with known vital status.
Valve-related complications. Follow-up data forms were
designed to collect the specific data items making up the
definitions of valve-related complications (see later). The
final decision as to whether a valve-related complication
occurred was made by consensus of a subcommittee (see
Appendix) that reviewed the information in the data forms
without knowledge of valve type. This subcommittee also
reviewed all deaths using a summary data form containing
relevantinformation,clinical summaries and autopsy reports
to determine whether death may have been due to a valve-
related complication. Patients whose death was classified
as cardiac, but in which the relation to the prosthetic valve
was uncertain (usually because of sudden death and no au-
topsy), were counted as having had a fatal valve-related
complication. The following definitions of valve-related
complications were used.
Systemic embolism: Sudden onset of objective neuro-
logic deficit > 48 hours after valve replacement and lasting
>30 minutes in the absence of another more plausible etiol-
ogy; or sudden onset of flank pain with hematuria and ab-
normal renal scan; or sudden onset of a cold painful limb
with loss of pulse; or myocardial infarction with arterio-
graphically normal coronary arteries occurring > 48 hours
after valve replacement; or acute onset of bowel infarction
with thromboembolism diagnosed at surgery or autopsy.
Valvular regurgitation: Diagnosed only when it was the
primary indication for prosthetic valve replacement or repair
or the primary cause of death (subdivided into periprosthetic
or central valvular on the basis of the operative report or
autopsy findings).
Endocarditis: Fever plus two or more positive blood
cultures for the same organism in the absence of another
more obvious form of bacteremia (for example, pneumo-
coccal pneumonia resulting in pneumococcal bacteremia);
or bacteria cultured from or identified histologically in pus
or vegetationon or near the prosthetic valve at repeatsurgery
or autopsy; or bacteria cultured from or identified histolog-
ically in a septic embolus.
Bleeding: Resulting in death, or decrease in hemoglobin
22 .0 g. or transfusion of 2 2 unitsof blood, or intracerebral
hemorrhage or gross hematuria leading to hospitalization or
urologic manipulation or stopping anticoagulationor lasting
> 24 hours, or deep space hematomaor hemarthrosis leading
to hospitalization or disability. Significant bleeding occur-
ring ::;48 hours of cardiopulmonary bypass was not con-
sidered valve related.
Valve thrombosis: Obstruction or malfunction of the
prosthetic valve by thrombus resulting in reoperation or
death (confirmed at autopsy).
Valve obstruction not due to thrombosis: Nonthrombotic
prosthetic valve obstruction resulting in reoperation or death
(confi rmed at autopsy).
Reoperation: Reoperation on prosthetic valve not due to
any of these complications.
Statistical analyses. Comparisonof patientsrandomized
to the two valve types was made using the chi-square test
for discrete variables and the unpaired Student's t test for
continuous variables. No correction for multiple compari-
sons was made.
Two end points were defined in the protocol: I) death
from any cause, and 2) nonfatal plus fatal valve-related
complications. A likelihood ratio statistic was used to com-
pare the time to death or first complication for patients with
the two valve types (13). The critical values for the test
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statistic and the powerof the tests were computed using the
simulation technique of Canner et al. (14,15). The critical
values for rejection of the null hypothesis were estimated
by simulation of the study 2,000 times with patient entry,
follow-up and occurrence of end points projected for the
total study based on initial experience. A sloping boundary
to the rejection region was selected (that is, thecriticalvalue
decreasedas the study proceeded), allowing forgreaterchance
variation when the numberof events was small and follow-
up time short. This simulation assumes that the data were
examined at 6 month intervals over 7 years (14 times total).
For the present analyses, the critical value for death as the
end point is 4.66 for the subgroup with the larger aortic
valve, 4.67 for the subgroup with the smaller aortic valve,
4.49 for the total aortic valve group and 4.34 for the mitral
valve group. For valve-related complications, the critical
value is 4.84 for the subgroup with the larger aortic valve,
4.59 for the subgroup with the smaller aortic valve, 4.43
for the total aortic valve group and 4.41 for the mitral valve
group (7) . The statistical power to detect a 15% difference
in 5 year death rate (15 versus 30% for aortic valve re-
placement and 30 versus 45% for mitral valve replacement)
was 94 and 59%, respectively, assuming sample sizes of
282 and 180 and alpha of 0.05. Similarly, the power to
detect a 20% difference in valve-related complication rates
(15 versus 35% at 5 years) was 99% for the larger aortic
valve subgroup and 94% for the mitral valve group.
Curves representing survival or complication-free time
were constructed using the life table technique for illustra-
tive purposes. However, the primary statistical analyses test-
ing the primary hypotheses were the likelihood ratio statistic
as described earlier. The likelihood ratio statistic and the
life table analyses shown in the figures can describe only
time to a first event. Patients having more than one valve-
related complication cannot be described by this technique.
Thus, an additional table has been constructed to show all
valve-related complications so long as the original random-
ized valve remains in place. Because three of the baseline
variables were significantly different between patients re-
ceiving a mitral bioprosthesis and those receiving a mitral
mechanical prosthesis, survival was also comparedbetween
the two valve type groups adjusting for differences in base-
linevariables usingthe Cox regression model(16). A patient
is no longer followed up for nonfatal complications after
replacement of the randomized prosthesis but continues to
be included for survival analysis.
Results
Comparison of randomization groups. Some of the
baseline characteristics used to compare patients receiving
the bioprosthesis with those receiving the mechanical pros-
thesis are shown in Tables 2 and 3. Variables not shown
(partial pressure of arterial oxygen [Pao-], creatinine , car-
Table 2. Comparison of Baseline Characteristics in Patients Receiving a Mechanical Prosthesis
or a Bioprosthesis (means and SD of continuous variables)
Aortic Mitral
Mechanical Bioprosthesis Mechanical Bioprosthesis
(n = 198) (n = (96) (n = 88) (n = 93)
Variable Mean SO Mean SO Mean SO Mean SO
Age (yr) 59.1 8.1 60.2 7.9 58.8 7.8* 56.3 7.1*
Estes score 4.43 3.17* 3.74 2.76* 2.11 2.13 2.50 2.18
av02 diff (mill 00 mil 5.20 1.13 5.33 1.19 5.54 i .u r 6.24 1.46t
Cardiac index (liters/min 2.61 0.64 2.54 0.58 2.33 0.68 2. 17 0.54
per rrr')
PA systolic (mm Hg) 34.2 16.8 32.7 14.7 51.4 18.8 48.4 18.9
Mean PAW (mm Hg) 22.1 11.2 21.5 9.8 34.3 12.5 31.9 12.8
Mean valve gradient 60.8 22.0 58.9 17.9 15.9 5.9 16.2 6.1
(mm Hg; stenosis only)
LVEOVI (ml/nr')
Stenosis 76.0 23.8 77.0 24.9 82.3 23.0 84.8 23.3
Mixed 106 46.7 106 29.5 108 32.9 11 6 46.9
Regurg 135 39.2 139 44.9 126 53. 1 125 45.4
Ejection fraction 56.0 16.0 58.3 14.2 52.5 14.6 54.7 15.2
Regurgitant volume 4.5 2.7 4.7 4.2 4.8 4.2 7.3 5.0
(liters/min; regurg only)
*Means are different with a significance of p < 0.05; t means are different with a significance of p <
0.001. av02diff = arterial-mixed venousoxygendifference; LVEOVI = left ventricular end-diastolic volume
index; Mixed = patients with mixedaortic stenosis and regurgitation or mixedmitral stenosis and regurgitation;
PA systolic = pulmonary artery systolic pressure; PAW = pulmonary artery wedge pressure; stenosis
patients with aortic or mitral stenosis; Regurg = patients with aortic or mitral regurgitation.
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Table 3. Comparison of Baseline Characteristics in Patients Receiving a Mechanical Prosthesis
or a Bioprosthesis (distribution of discrete variables),
Aortic Position Mitral Position
Mechanical Bioprosthesis Mechanical Bioprosthesis
(n = 198) (n = 196) (n = 88) (n = 93)
Variable N ('k) N (c,i ) N (% ) N ( ~. )
Prior MI 21 ( I I) 2<) ( 15) 15 (17)* 6 (7)*
Functional class
I to III 176 (89) 174 (89) 79 (90) 74 (80)
IV 22 ( I I) 22 ( I I) <) (10) 19 (20)
Rest ECG: ST segment 93 (48) 87 (46) 33 (38) 31 (34)
depression ?- I mrn
Coronary stenosis ?- 509;
0 100 (52) 106 (56) 57 (65) 64 (69)
One vessel 36 (19) 29 (15) II (13) 12 (13 )
Two vessels 38 (20) 27 (14) 13 (15) 8 (9)
Three vessels 18 (9) 28 (15) 7 (8) <) (10)
Preoperative valve lesion
AS or MS 93 (47) 98 (50) 27 (32 ) 27 (3 1)
AR or MR 46 (23) 43 (22) 33 (39) 26 (29)
AS/AR or MS/MR 47 (24) 46 (23 ) 15 (18) 24 (27)
Multivalvular II (6) 9 (5) <) (II ) II (13)
*p < 0.05. AR = aortic regurgitation; AS = aortic stenosis: AS/AR = mixed aortic stenosis and regur-
gitation: ECG = electrocardiogram: MI = myocardial infarction: MR = mitral regurgitation; MS = mitral
stenosis: MS/MR = mixed mitral stenosis and regurgitation: N = number of patients having characteristic.
diothoracic ratio, aortic systolic pressure and left ventricular
end-diastolic pressure) were not significantly different be-
tween valve type groups. For patients undergoing aortic
valve replacement, a significant difference was observed in
only I of the 20 examined characteristics; patients receiving
the mechanical prosthesis had slightly more ECG evidence
of left ventricular hypertrophy assessed by the Estes score
compared with patients receiving the bioprosthesis. Statis-
tically signifi cant differences were found in 3 of the 20
variables comparing patients receiving a mitral bioprosthesis
versus a mechanical prosthesis; patients receiving a me-
chanical prosthesis had a slightly greater mean age, a lower
mean arteriovenous oxygen difference and a higher inci-
dence of prior myocardial infarction.
Operative mortality. Overall operative mortality was
7.7 % (44 of 575) ; it was 8. 6% (1 2 of 139) in the group
with the larger size aortic bioprosthetic valve. 3.4°k (5 of
145) in the group with the larger size mechanical aortic
valve. 10 .5% (6 of 57 ) in the group with the smaller size
bioprosthetic aortic valve, 13 .2% (7 of 53) in the group
with the smaller size aortic mechanical valve, 6 .5% (6 of
93) in the mitral bioprosthetic valve group and 9 . 1% (8 of
88) in the mitral mechanical valve group. The overall op-
erative mortality rate in this study is virtually identical to
that reported by the New York State Department of Health
(17 ). which reported an overall mortality rate of 7.9% for
8 ,698 patients operated on from 1979 to 1981. a similar
time period. In the present study, both age and coronary
disease were significant risk factors for operative death. The
operative mortality rate was 4 .5 % in 3 10 patients without
coronary artery disease, but 11.7% in 265 patients with one
or more ::::50% stenoses in a major coronary artery. Simi-
larly. operative mortality was 4.5 % in 289 patients < 60
years compared with 11.2% in 286 patients ::::60 years.
Aortic valve replacement. Survival. There was no dif-
ference in survival for the 198 patients undergoing aortic
valve replacement with the mechanical prosthesis (58 deaths)
compared with that in the 196 patients receiving the bio-
prosthesis (59 deaths) (Table 4, Fig. I). The 5 year survival
probability was 0.72 ± 0.03 for the mechanical valve group
and 0 .70 ± 0 .04 for the bioprosthesis group. Although
patients receiving a 2 1 or 23 mm aortic valve tended to
have poorer survival than those receiving a larger valve.
there were no differences in survival between patients with
a mechanical valve or a bioprosthesis in either of the aortic
valve size subgroups.
V(J Ive-related complications. These occurred signifi -
cantly more frequently in patients receiving the mechanical
prosthesis compared with those receiving the bioprosthesis
(p < 0 .05) (Table 4 . Fig. 2) . The probability of freedom
from a fatal or nonfatal valve-related complication at 5 years
was 0 .53 ± 0 .04 for the mechanical prosthesis group and
0 .63 ± 0 .04 for the bioprostliesis group. The two aortic
valve size subgroups showed similar differences in valve-
related complications by valve type; however, the difference
in the larger valve size subgroup did not reach statistical
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Table 4. Comparison of Occurrence of End Points in Patients Receiving a Mechan ical Prosthesis or a Bioprosthesis
Mechanical Prosthesis Bioprosthesis
5 Year Prob 5 Year Prob
Statistical Comparison
No. of Pts With Event No. of Pts With Event
Valve of Being of Being Critical
Subgroup N 00;30 Days > 30 Days Event Free N 00; 30 Days > 30 Days Event Free Chi-Square Value
All Deaths
Aortic 53 7 11 0 .68 ± 0.07 57 6 15 0.57 ± 0.G7 0.268 4.67
(21.23 mm)
Aortic 145 5 35 0 .73 ± 0.04 139 12 26 0 .74 ± 0.04 0 .6 17 4.66
( ~25 mrn)
All aortic 198 12 46 0.72 ± 0.03 196 [8 4\ 0 .70 ± 0.04 0 . 105 4.4 9
Mitral 88 8 32 0. 58 ± 0.06 93 6 23 0 .70 ± 0.05 3.25 4.34
Valve-Related Deaths
Aortic 53 4 0.88 ± 0.05 57 2 9 0 .73 ± 0.0 7
(2 1.23 mrn)
Aortic 145 2 16 0.87 ± 0.03 139 2 18 0 .85 ± 0.03
( ~ 25 mm)
All aort ic 198 3 20 0.87 ± 0.03 \96 4 27 0.82 ± 0.03
Mitral 88 2 23 0 .70 ± 0.06 93 0 \8 0 .8 1 ± 0 .04
Nonfatal Valve-Related Complications
Aortic 53 18 0.55 ± 0.08 57 5 7 0 .77 ± 0.06
(2 1.23 mm)
Aortic 145 9 38 0 .64 ± 0.05 139 6 25 0. 74 ± 0.04
( ~25 mm)
All aortic 198 10 56 0.62 ± 0.04 \96 \1 32 0.75 ± 0.04
Mitral 88 5 24 0 .57 ± 0.07 93 5 14 0.78 ± 0.05
All Valve-Related Compl ications (fatal and nonfatal)
Aortic 53 2 22 0.4 6 ± 0.08 57 7 12 0 .6 1 ± 0.G7 4.80 4.59
(2 1.23 mm)
Aortic 145 \1 5\ 0.56 ± 0.04 \39 9 38 0.64 ± 0.05 2.28 4.84
( ~25 mm)
All aortic \98 13 73 0 .53 ± 0.04 196 16 50 0 .63 ± 0.04 5.64 4.43
Mitral 88 8 34 0.45 ± 0.06 93 5 27 0 .67 ± 0.05 4.60 4.41
N = number of patients; Prob = probability : Pts = patients.
significance at p < 0.05. Data on deaths due to a valve-
related complication and nonfatal valve-related complica-
tions have been included in Table 4, but statistical com-
parisons have not been calculated because these end points
are not the primary end points of the study. Summing valve-
related deaths and nonfatal complications does not equal all
valve-related complications, because a nonfatal complica-
tions and a valve-related death may occur in the same pa-
tient; this table considers only the fi rst event to occur in any
patient.
Bleeding. Table 5 shows the distribution of all valve-
related complications; multiple valve-related complications
in a single patient are counted in this table. Clinically sig-
nifi cant bleeding was, by far, the most common compli-
cation, accounting for 58% (103 of 177) of all complications
observed in patients undergoing aortic valve replacement
and accounting entirely for the increased complication rate
observed in patients receiving the mechanical prosthesis.
Bleeding was believed to be the primary cause of death in
10(10%) of 103episodes. The 5 year probability of freedom
from bleeding was 0.67 ± 0.04 for patients with an aortic
mechanical prosthesis and 0.85 ± 0.03 for patients with an
aortic bioprosthesis. A warfarin anticoagulant was being
used immediately before 41% of the bleeding episodes in
patients with a bioprosthesis and 96% of the bleeding epi-
sodes in patients with a mechanical prosthesis. Of the bleed-
ing episodes occurring while the patient was receiving war-
farin, the precedingprothrombin time was in the therapeutic
range specifi ed by the protocol (2.0 to 2.5 times the control)
in 17%, below the therapeutic range in 45%, above the
therapeutic range in 15% and unknown in 23%. If the pro-
thrombin times are classified by the currently more com-
monly used therapeutic range of 1.5 to 2.5 times the control
value, 45% were within the therapeutic range, 17% were
below, 15% were above and 23% were unknown. Among
patients with a bioprostheticvalve the sites of bleeding were
l ACC Vol. 10. No.4
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Figure I. Actuarial analysis of survival using death from any
cause as the end point. Comparison of patients undergoing aortic
valve replacement with a bioprosthesis (Bio) versus patients re-
ceiving a mechanical (Mech) prosthesis. One standard error of the
survival probability (Prob) is shown at 2. 4 and 6 years by the
vert ical bar s. The numbers adjacent to the points at 2. 4 and 6
years are the number of patients available fo r observat ion at that
time.
similar for those with and without anticoagulant therapy;
34% ( 10of 29) of the episodes were of gastrointestinal origin
and 41 % (12 of 29) were from the urinary tract.
Thromboembolism . On the other hand. the total number
of systemic embolic episodes was somewhat greater in pa-
tients with a bioprosthesis (20 episodes) compared with
patients with a mechanical prosthesis (15 episodes). How-
ever. because more patients with an aortic bioprosthet ic
valve had more than one embolic episode. life table analysis
shows that the probabilities of freedom from systemic em-
bolism were similar for patients with the two valve types;
the 5 year probability of remaining free from systemic em-
bolism was 0.92 ± 0.02 for patients with a mechanical
prosthesis and 0 .9 1 ± 0.02 for patients with a bioprosthesis.
A warfarin anticoagulant was being used' at the time of
systemic embolization in 35% of episodes in patients with
a bioprosthesis and 100% of the episodes in patients with
a mechanical prosthesis.
Endocarditis . This occurred with nearly equal frequency
in patients in the two valve type groups.
Reop eration on the randomized valve. This was per-
formed in 19 patients undergoing aortic valve replacement.
9 with a mechanical prosthesis and 10 with a bioprosthesis
(Table 6). The most frequent cause was perivalvular re-
gurgitation (in eight patients. four with a mechanical pros-
thesis and four with a bioprosthesis); in six patients (five
with a bioprosthesis and one with a mechanical prosthesis)
the randomized valve was changed at the initial operation
because it could not be seated properly. There were no
rcoperations for primary valve failure. and no deaths have
been attributed to primary valve failure.
Mitra l valve replacement. Survival. There was a trend
toward improved survival in patients undergoing mitral valve
replacement with a bioprosthesis (29 deaths) compared with
those receiving a mechanical prosthesis (40 deaths); how-
ever. differences are not statistically significant because the
test statistic for difference in death rates (3.2 5) does not
exceed the critical value (4.34) (Table 4. Fig. 3). The 5
year survival probability is 0.58 ± 0.06 for patients with
the mechanical valve and 0.70 ± 0.05 for patients with the
bioprosthesis. Most (If the difference in deaths was due to
valve-related deaths. 25 in patients with a mechanical pros-
thesis and 1X in patients with a bioprosthesis (Table 4).
Yalvc-related complications. These occurred signifi-
cantly more frequently in patients with a mechanical mitral
prosthesis than in those with a mitral bioprosthesis (Table
4, Fig. 4) . The probability of freedom from a valve-related
complication at 5 years was 0.45 + 0.06 for patients with
a mechanical prosthesis and 0.67 ± 0.05 for patients with
a bioprosthesis.
Bleeding. As in patients with aortic valve replacement.
the most frequent valve-related complication was clinically
significant bleeding. which accounted for 45% of all com-
plications (Table 5) . The difference in occurrence of bleed-
ing accounted for most of the increase in valve-related com-
plications in patients with a mechanical mitral valve. although
reoperation or death due to periprosthetic regurgitation was
also somewhat more frequent in this group (Table 5). Death
occurred as the result of bleeding in 16% of episodes (7 of
43). The probability of freedom from clinically significant
bleeding at 5 years was 0.64 ± OJn for patients with a
mechanical prosthesis and 0.88 ± 0.04 for patients with a
bioprosthesis. A warfarin anticoagulant was being used at
the time of the bleeding episode in 97% of patients with a
Figure 2. Actuarial analysis of time to tirst valve-related COIll -
plication (fatal or nonfatal). Comparison of patient s undergoing
aortic valve replacement wi th a bioprosthesis versus those receiv-
ing a mechanical prosthesis. Format and abbreviations as in Fig-
ure I .
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Table 5. Distrib ution, by Type , of Tota l Number of Compl icatio ns
Aortic Position Mitral Position
Mechanical Bioprosthesis Mechanical Bioprosthesis
Complications Comp Death Comp Death Comp Death Comp Death
Bleeding 74 5 29 5 32 5 II 2
Systemic embolism 15 0 20 4 10 0 10 I
Endocarditis II 3 <) 3 7 5 I I 4
Valvular regurgitation 7 4 5 I 8 2 2 2
Valve thrombosis 2 I I I I I I
Valve obstruction. 0 0 0 0 I 0 0
nonthrombotic
Reoperation not due 0 0 4 0 0 0
to any of the above
Total 109 13 68 15 59 14 36 10
Camp = total number of fatal and nonfatal complications; Death = number of patients dying of compli-
cation.
mechanical prosthesis and 55% of patients with a biopros-
thesis. For patients taking an anticoagulant, the immediately
preceding prothrombin time was within the therapeutic range
specified by the protocol in 22%, below the therapeutic
range in 51%, above the therapeutic range in 5% and un-
known in 22%. If the prothrombin times are classified by
the currently more commonly used therapeutic range of 1.5
to 2.5 times the control, 62% were within the therapeutic
range, II % below, 5% above and 22% unknown.
Thromboembolism. Systemic embolism occurred with
equal frequency in patients with a mechanical or a tissue
prosthesis. The 5 year probability of freedom from systemic
embolism was 0.89 ± 0.04 for patients with a mechanical
prosthesis and 0.91 ± 0.03 fo r patients with the b iopro s-
thesis. An anticoagulant was being used at the time of the
systemic embolism in all episodes in patients with the me-
chanical prosthesis and 33% of episodes in patients with the
bioprosthesis.
Reoperation on the randomized mitral prosthetic valve .
This was performed in eight patients with a mechanical
prosthetic valve (9. 1%) and four patients with a biopros-
thetic valve (4.3%) (Table 6). This difference was due to a
higher frequency of reoperation for perivalvular regurgita-
tion in the mechanical valve group. No instances of primary
valve failure were identified either at reoperation or at au-
topsy.
Discussion
No prosthetic heart va lve ye t de vel oped approaches the
normal human valve in either hemodynamic function or
freedom from complications (18,1 9), two factors that are
Table 6. Reasons for Repeat Operation on Randomized Valve Prosthe sis
Aortic Position Mitral Position
Mechanical Bioprosthesis Mechanical Bioproslhesis
(n = 198) (n = 1lJ6) (n = 88) (n = 93)
N (% ) N (%) N (% ) N (% )
Endocarditis 2 (1.0) I (0.5) (1.1) 2 (2.2)
Valve thrombosis 1 (0.5) 0 (0) (1. 1) 0 (0)
Regurgitation
Central valvular 0 (0) 0 (0) 0 (0) 0 (0)
Perivalvular 4 (2.0) 4 (2.1) 6 (6.8) I ( I. I )
Valve change during
initial operation (0.5) 5 (2.6) 0 (0) 0 (0)
Other (0.5)* 0 (0) 0 (0) I (r.nt
Total 9 (4.5) 10 (5.1) 8 (9. 1) 4 (4.3)
*Anticoagulant-related hemorrhage. t Repair of left ventricular to right atrial shunt 3 months after initial
operation; prosthetic valve was changed even though it was normal.
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Figure 3. Actuarial analysis of survival using death from any
cause as the end point. Comparison of patients undergoing mitral
valve replacement with a bioprosthesis versus those receiving a
mechanical prosthesis. Format and abbreviations as in Figure I.
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Figure 4. Actuarial analysis of time to first valve-related com-
plication (fa ta l or nonfatal ). Compari so n of patient s undergoing
mitral valve replacement with a bioprosthesis versus those receiv-
ing a mechanical prosthesis. Format and abbreviations as in Fig-
ure I.
with a proved record of at least 4 to 5 years. and 2) valves
in widespread use. Although this choice of study valves was
made 10 years ago, the Hancock porcine heterograft and
Bjork-Shiley spherical disc valves continue to be widely
used as representatives of these two classes of valves. Be-
cause of preliminary data indicating high prosthetic valve
gradients in the smaller sizes of the aortic bioprosthesis. the
initial protocol excluded patients requiring a 21 or 23 mm
valve from randomization. When the modified orifice Han-
cock porcine heterograft became available in the second year
of the study, patients undergoing aortic valve replacement
with a 21or 23 mm valve were randomized also. The mod-
ified orifice porcine heterograft differs from the standard
valve in that the right coronary cusp containing a portion
of interventricular septum (thought to be obstructive) is re-
placed with a left or noncoronary cusp from another valve.
Although these patients were randomized as a separate group,
mostof the data in this report are presented for the combined
aortic valve replacement group, because the comparisons
of the two valve types were similar in the two aortic valve
size groups.
Randomization. During the 5 year entry period of this
study. 1.078 patients underwent valve replacement at the
13 participating medical centers. Most (287) of the 503
patients not randomized did not meet protocol requirements
Crable I ).
There were seven randomization errors in which a patient
assigned a mechanical prosthesis received a bioprosthesis.
and five errors in which the converse occurred. The most
frequent reasons for these errors were the selection of a
randomization envelope from the wrong end of the sequence
of envelopes or from the incorrect set (stratum) of envelopes.
The analyses presented in this paper were all calculated
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important determinants of the choice of prosthetic valve and
the timing of replacement. The VA Cooperative Study of
Valvular Heart Disease began entering patients in 1977 to
address these important questions. We have previously re-
ported (20) slightly better hemodynamic function 6 months
postoperatively for the mechanical valve compared with the
tissue prosthesis in the aortic position, but no difference for
mitral valves. The present study is the fi rst interim report
on the primary end points of this randomized trial comparing
survival and valve-related complications in patients receiv-
ing either a mechanical heart valve (the Bjork-Shiley spher-
ical disc prosthesis) or a bioprosthetic valve (the Hancock
porcine heterograft). Although survival was not significantly
different between patients receiving the tissue or mechanical
valve in either the aortic or the mitral position, the occur-
rence of valve-related complications was signifi cantly less
in patients with the bioprosthesis.
Study group. During the planning of this study. a de-
cision was made to limit patient entry to men. because of
the small number of women undergoing valve replacement
in VA medical centers. Thus. our patient group is not nec-
essarily representative, particularly for mitral valve replace-
ment for which women make up half or more of most series
(21,22). On the other hand, aortic valve disease is more
common in men. More importantly, we are not aware of
any data indicating that valve-related complications are sex
dependent; to the contrary, two important valve-related
complications, degeneration of porcine heterografts (23) and
endocarditis (24), appear to occur equally in men and women.
We believe that the results of this trial may be applicable
to women undergoing valve replacement as well.
Choice of study valve prostheses. In choosing prostheses
representative of mechanical and bioprosthetic valves, the
planning committee used the following criteria: I) valves
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according to valve assigned; however. when the testing of
the two major end points (survival and valve-related com-
plications) (Table 4) was repeated by valve received. no
difference in the results was observed.
Entry characteristics. That the randomization process
worked effectively is demonstrated by the comparability in
baseline characteristics of patients receiving the biopros-
thesis and those receiving the mechanical prosthesis (Tables
2 and 3). The four statistically significant differences of 40
comparisons made are only slightly more than would be
expected by chance alone. However, three of these differ-
ences (age. arterial-mixed venous oxygen difference and
frequency of prior myocardial infarction) occurred in pa-
tients undergoing mitral valve replacement. Therefore. we
applied the Cox multiple regression model for survival anal-
ysis (16) to adjust for these differences in baseline char-
acteristics. This is a post hoc analysis not specifi ed in the
protocol. The results of these analyses adjusting for these
three variables slightly reduce the statistical significance.
For deaths. the probability (p) value for valve type when
this is the only independent variable in the model is 0.0536;
when the three variables are also included as independent
variables, the p value for valve type increases to 0.1487.
These same calculations for complications result in a p value
of 0.0117 and 0.0837. respectively. Although adjustment
for these chance differences in baseline variables between
patients in the two mitral valve type groups slightly reduces
the level of statistical significance, we emphasize that the
analyses presented in Table 4 are those planned in the pro-
tocol and we do not believe that the overall conclusions are
altered by these post hoc analyses.
Statistical analyses. To minimize the likelihood of pro-
ducing chance differences, we have applied statistical hy-
pothesis testing only to the two end points (all deaths and
all valve-related complications, fatal and nonfatal) in each
of the subgroups (smaller- and larger-sized aortic valves and
mitral valves) specified in the protocol. Although eight anal-
yses (two end points, four groups) were performed (Table
4). the data are presented with no adjustment for multiple
comparisons, because we believe that clear guidelines for
such an adjustment do not exist. On the other hand. the
critical values (the value the test statistic would have to
exceed to achieve statistical significance) are conservative,
because we calculated them to adjust for 14 examinations
of the data during the course of the study (7), when in fact
the data were examined only 9 times. The test statistic for
the difference in valve-related complications for the com-
bined aortic valve replacement group is sufficiently large as
to be significant. regardless of any adjustment for multiple
comparisons. For the mitral valve replacement group, the
difference in probability of freedom from valve-related com-
plication is even greater than for the aortic valve replacement
group (Table 4, Fig. 2 and 4). However, because of the
smaller number of subjects studied, the test statistic was
closer to the critical value (that is, closer to being nonsig-
nificant) and might be affected by adjustment for multiple
comparisons. Because the analyses shown in Table 4 use
only the first event occurring in a patient, the sum of events
listed for valve-related deaths and nonfatal valve-related
complications may be slightly more than the number of
events listed for all valve-related complications.
The calculations of the test statistics (Table 4) and the
life table analyses for the fi gures are based on the first event
occurring in any given patient and treat all valve-related
complications equally. Table 5 shows the distribution of all
complications (including multiple complications in a single
patient) by the type of complication. For the aortic valve
replacement group. 21 patients receiving the mechanical
prosthesis and 13 patients receiving the bioprosthesis had
two to four complications each; comparable figures for the
mitral valve replacement group are 17 and 7. respectively.
Complications. In designing the protocol for this ran-
domized trial, it was our intent to defi ne valve-related com-
plications to be significant. morbid events. That this goal
was achieved is indicated by an overall mortality rate for
all complications of 19% (52 of 272: Table 5); no compli-
cation had a mortality rate < 9%. For this reason valve
regurgitation and obstruction were not diagnosed unless they
resulted in reoperation or death. This conservative definition
may have resulted in an underestimation of the overall in-
cidence of clinically significant valve regurgitation or ob-
struction. On the other hand. we counted every death that
could not be classifi ed (usually because it occurred suddenly
outside of the hospital with no autopsy) as a valve-related
death: undoubtedly, there were some primary arrhythmic
deaths unrelated to valve dysfunction in this group.
Blinding of either the subjects or the physicians caring
for the patients is neither possible nor ethical. Yet. there is
considerable subjectivity in the determination of whether a
valve-related complication has occurred, leaving room for
bias if the valve type is known. Therefore. the subcommittee
responsible for making the final determination as to whether
a complication occurred was blinded to valve type. The
follow-up data forms were designed to collect objective
information relevant to the definitions of valve-related com-
plications. For patients with suspected valve-related com-
plications, copies of the appropriate portions of this data
form were distributed to the subcommittee. which made the
final determination by consensus at periodic conference calls.
The assignment of cause of death was more difficult. Ini-
tially. a data form was also used, but the committee found
the narrative information contained in the fi nal summary,
operative report and autopsy report useful in this detenni-
nation. These reports were reviewed by a fourth individual,
who deleted references to valve type. Although very time
consuming, we felt that this process was essential to elim-
inate bias in the assignment of valve-related complications.
To our knowledge, this is the only study of outcome after
lAC C Vol. 10. No.4
October 1987:719- 32
HAMMERMEISTER ET AL.
RANDOMIZED TRIAL OF HEART VALVE PROSTHESES
729
heart valve replacement in which this type of blinding has
been done.
Bleeding. Clinically significant bleeding occurred more
than twice as frequently in patients receiving the mechanical
prosthesis as in those receiving the bioprosthesis (Table 5).
In the aortic valve replacement group , the increased fre-
quency of bleeding accounted for all of the difference in
valve-related complications observed between patients in
the two valve type groups . In patients undergoing mitral
valve replacement , prosthetic valve regurgitation resulting
in reoperation or death also occurred more frequentl y in
patients receiving the mechanical prosthesis.
The annual rate of occurrence of bleeding was high
(6.6% for patients with the aortic mechanical prosthesis,
3.0% for patients with the aortic bioprosthesis, 7.2% for
patients with the mitral mechanical prosthesis and 2.4% for
patients with the mitral bioprosthesis). The previously re-
ported rate of bleeding complications reported varies widely.
Bjork and Henze (25) reported a 6 .3% annual rate of "se-
rious bleeding" in 413 patients followed up an average of
4.8 years. Hill et al. (26) reported an annual rate of 6.0%
in 77 patients with a porcine heterograft. In 50 I patient s
receiving warfarin (onl y 60% with a prosthetic valve) fol-
lowed up for an average of 2.4 years Forfar (27) found an
annual 4.3% rate of bleeding episodes that required medic al
attenti on ; 39% of episodes were life threatening . Larsen et
al . (28) reported that 3.2 %/year of I 10 patients with a Bjork-
Shile y prosthesis had serious bleeding complications. Gon -
zalez-Lavin et aJ. (29) found an annual rate of I. 9% in I J5
patients with a porcine heterograft who were taking warfarin
as an anticoagulant. A very low annual rate of " major
bleeding" (0.5%) was reported by Lepley et aJ. (30) in 547
patients with a Bjork-Shiley prosthesis .
There are several reasons why there might be marked
disparity in the reported rates of bleeding. First. in pro-
spective studies, such as ours, in which the patients are seen
and questioned in regard to complications at regular inter-
vals, the rate of ascertainment of complications is likely to
be higher than with the single retro spect ive follow -up used
in many publi shed series. Second , the definition of a bleed-
ing complication undoubtedly is nonuniform. For example.
we counted every bleeding episode that tit the definition ,
even if there was a cause separate from the use of antico -
agulants . A number of our patients met the criteria for uri-
nary tract bleeding (gross hematuria leadin g to hospitaliza-
tion, urologic manipulation or stopping anticoagulation) as
a result of obstructive uropathy or transurethral resection of
the prostate, or both . Others met the criteria for a 2 g fall
in hemoglobin concentration or 2 unit transfusion in asso-
ciation with noncardiac surgery (often performed when an-
ticoagulant therapy had been stopped) . Finally, the level of
anticoagulation achieved is likely to vary. It is possible that
the therapeutic range for prothrombin time specified in our
protocol (2 to 2.5 times the control level) was too high.
The therapeutic range for prothrombin time for patients with
a cardiac valve prosthesis has never been subjected to sci-
entific scrutiny by examining the balance between throm-
boembolic phenomena and bleeding and prothrombin time ;
this is the subject of an upcoming analysis from the VA
Cooperati ve Study on Valvular Heart Disease. The thera-
peutic range in the initial protocol was the consensus of the
planning committee in 1975 and 1976 and probabl y rep-
resented practice at that time . It is our impression that the
commonly used therapeutic range has gradually fallen, such
that most patients are now maint ained at 1.5 to 2 times the
control level.
Systemic embolism. In patients with an aortic prosthesis,
the total number of systemic embolic episodes was some-
what greater in those with a bioprosthetic valve (20 episodes)
than in those with a mechanical valve (15 episodes), but
the probabil ity of being free from an embolus at 5 year s
was similar in the two valve groups (0 .92 and 0.91, re-
spectively). Thu s, there is no difference in risk of embol-
ization between patients with a tissue or mechanical valve
in the aortic position when those with a mechanical pros-
thesis recei ve anticoagulant therapy. Similarly, the risk of
emboli zation is identical in patients with a tissue or me-
chanic al mitral valve prosthesis .
Endocarditis . Endocarditis occurred with nearl y equal
frequency in patients with a tissue or mechanical valve in
both the aortic and mitral replacement groups. Death or
reoperation , or both . due to endocarditis was also similar
between the two valve type subgroups, indicating that the
commonly held belief that a tissue valve would be more
amen able to antibiotic sterilization is probably incorrect.
This lack of difference between the two valve types is log-
ical , because the infection usually occurs between the sew-
ing ring and the native valve anulus.
Other randomized trials. Bloomfield et al. (31) re-
centl y reported on a similar randomized trial performed in
Edinburgh, Scotland comparing a bioprosthesis (either Han-
cock or Carpentier-Edwards porcine heterograft) with a me-
chanical prosthesi s (Bjork-Shiley) . In addition to using two
different bioprostheses and including patient s undergoing
double valve replacement , their patients were younger, less
symptomatic and had a much lower incidence of docu-
mented coronary artery disease (Table 7). Survival , oper-
ative mortality and incidence of reoperation were similar
among patients in the three valve type groups in their stud y
and were similar to our results (Table 8). An exception is
survival in patients recei ving the mechanical prosthesis in
the mitral position : 7 year probability of survival was lower
in our patient s (0 .42) than in theirs (0 .59). In contrast to
our findings, Bloomfield et al. (31 ) report that bleeding
complications were rare . They reported a I to 1.5% annual
rate of " complication of antic oagulation" (not further de-
fined), whereas our patients with a mechanical prosthetic
valve experienced a 6 to 7%/year risk of clinically significant
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Aortic Valve Replacement Mitral Valve Replacement
Edinburgh VA Edinburgh VA
Variable (n = 210) (n = 394) (n = 262) (n = 181)
Age (yr)
< 50 29 II 34 15
50 to 65 53 63 55 70
> 65 17 26 12 14
Funcdonal class
I ,II 53 29 41 12
II1 ,IV 47 70 59 87
Valve lesion
Stenosis 30 51 30 36
I i . . 26 24 12 39Regurgitation
Stenosis/regurgitation 46 25 58 26
Coronary disease 8.6 44 5.3 41
Prior valvotomy 52 13
VA = Veterans Administration .
bleeding. Furthermore, their rate of "complication of an-
ticoagulation." was slightly higher in patients with a bio-
prosthetic valve than in patients with the mechanical valve-
the reverse of our results. Some of this difference may be
due to our counting all bleeding episodes meeting protocol
criteria (including those in close proximity to surgical pro-
cedures and those in patients not taking anticoagulants) .
Nevertheless, the bleeding episodes directly attributable to
anticoagulation were approximately 4 to 5%/yeat as sug-
gested by the diffe rence in rates between patients with the
bioprosthesis and those with the mechanical prosthesis . The
reasons for these differences are unclear. On the other hand,
the incidence of system ic embolism appeared to be sub-
stantially higher in all subgroups undergoing mitral valve
replacement in the Edinburgh study (14 to 20%) compared
with ours (9 to 10%).
Primary prosthetic valve failure. We observed no in-
stances of primary failure of either valve . However, we
cannot exclude the possibility that some of our patients
classified as dying a cardiac death in which the relation to
the valve was uncertain (primarily sudden deaths without
autopsy) died of catastrophic valve failure . Furthermore ,
maximal follow-up in our study (8 years) is just at the
beginning of the period of accelerated bioprosthetic failure
reported in some nonrandomized series (23,32-34). Be-
cause of the possibility that bioprosthetic valve failure might
reverse the modest advantage we have observed for this
valve , follow-up of these patients is continuing for another
5 years .
Conclusions. Survival of patients receiving a biopros-
thetic valve is similar to that of patients receivi ng a me-
chanical prosthesis at an intermediate duration of follow-up
of 3 to 8 years (mean 5). Valve-related comp lications occur
more frequently in patients with a mechanical prosthesis
than in those with a bioprosthesis. This is largely due to a
substantial difference in clinically significant bleeding. The
very high rate of clinically significant bleeding with its at-
tendant substantial mortality rate of 12% leads us to reem-
Table 8. Comparison of Results of Veterans Administration and Edinburgh Randomized Trials (31)
Aortic Valve Replacement Mitral Valve Replacement
Edinburgh VA Edinburgh VA
BS H CE BS H BS H CE BS H
Number 108 46 56 198 196 129 49 84 88 93
Operative mortality (%) 7.4 II 5.4 6.1 9.2 5.4 6.1 16 9.1 6.5
7 Year Survival probability .70 .67 .72 .66 .63 .59 .65 .46 .42 .64
Emboli (% of patients) 7.0 15 9.4 6.6 9.2 20 20 14 9.1 9.7
Reoperation (% of patients) 4.6 8.7 1.8 4.5 5.1 5.4 10 7.1 9.1 4.3
BS = Bjork-Shiley valve; CE = Carpentier-Edwards porcine heterograft valve; H = Hancock porcine heterograft valve; VA = Veterans Ad-
ministration.
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phasize the need for a very careful search for a history of
previous bleeding problems in patients about to undergo
valve replacement. Further observation of patients in this
randomized trial currently in progress will further define the
relative advantages of these two types of cardiac valve
prostheses.
Appendix
Participants in thF Veterans Administration Cooperative Study on Valvular
Heart Disease (former participants are indicated by an asterisk)
I. Offices and Laboratory of the Co-Chairmen
Karl E. Hammermeister. 1\10 (Co-Chairman. Medical); Jacob Heller.
MD." William M. Hamilton. PhD." Cecil Burchfiel, PhD. MPH (Epi-
demiologist); John L. VanDamme,* Cathryn S. Miller." Susan Kelly."
Mary Ann pisen (Data rechnician); Steve Siefken.* Chris Hixson" (Echo-
cardiography Tecbnic], n): Barbara L. Buck." Sylvia Stokes." Helen
BrandmosISecretaryl, Denver, CO. Gulshan K. Sethi. MD (Co-Chairman.
Surgical); Margaret Garrison," Doris Bunting.* Lynne Rochester (Sec-
retary). Asheville. NC,
II. Participating VA Medical Centers, Participating Investigators and
Supporting Personnel
Albany, NY: George Bousvaros, MD,* Madeline Silverman." Ashe-
ville, NC: Lingarncneni Ramesh. MD.* Vassil Prokhov, MD,* Stewart
M. Scott. MD. Thomas Maley. MD. Andrew Oakes. PA* Hines, IL:
Robert P. Croke. MD,* Ming Hwang. MD. Philip Rice. MD,* Craig
Thatcher. MD.* Mary White. RN,* Loretta Murphy* Miami, FL: Barry
R. Alter. MD.* Rafael Sequeria, MD.* Abelardo Vargas. MD,* Frederick
Wideman. MD.* RobertChahine, MD.* Steven Heyman.* LeonardKeene."
Bob Andritsch." Andreas Palomo. MD. Paula Wozniak* Minneapolis,
MN: Gordon Pierpont. MD. Yoshio Sako. MD. Mary Park,* Mary John-
son,* Kathleen McGregor,* Peggy Kruse.* Sue Ewald* Oklahoma City,
OK: Eliot Schechter. MD. Ronald Elkins. MD. Dee Noel.* Palo Alto,
CA: Donald Bairn, MD.* Ned Robert. MD,* John Giacomini. MD. D.
Craig Miller. MD. Michael Jamond,* Diane Tovey* Richmond, VA:
Zubair ul Hassan. MD. Szabolocs Szentpetery, MD. Kathleen Wong."
Jean Ziercnberg." Juanita Mallory. RN.* San Antonio, TX: Bertram
Groves. MD.' Sherman Sorensen. MD.* Michael Crawford. MD. Fred-
erick Grover. MD. Sandra Baca Mancia.* Judy Vittitoe. RN.* San Diego,
CA: Allen Johnson MD.* Ralph Shabetai. MD. William Y. Moores. MD.
Glenda Dennis.* Patricia Reilly.* Lynn Prescott.* Cathy McNally Nielsen.
RN* Wadsworth, CA: Pravin Shah. MD.* Maylene Wong. MD. Joseph
S. Carey. MD.* John Witting. MD,* Betty Smith," Winifred Carnegie."
Nancy Sadler. RN.* West Haven, CT: Rubin Zito, MD.* Gary Kopf.
MD.* Richard Shaw. MD.* Michael Clernan, MD. John Elesteriades.
MD. Sabet Hashim. MD. Elaine Pendergast.* Carole Berman." West
Roxbury, MA: Edward D. Folland. MD. Shukri Khuri, MD. Stefani
Karaffa;" Lucy Painter.* Margaret Brew.* Cynthia Carbone.*
III. Executive Committee
Karl E. Hammermeister. MD (Co-Chairman). Denver. CO; Gulshan
K. Sethi. M.D. (Co-Chairman). Asheville. NC; Julianne Souchek, PhD*
(Study Biostatistician), Hines. IL; Alan Cantor. PhD (Study Biostatisti-
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